en.hdbuzz.net
Read the original →
AMT-130 Gene Therapy Slows Huntington's in Landmark Trial
UniQure Shares Soar After FDA Reversal on Its Huntington's Therapy
Bloomberg · Jun 17, 2026 Standard
UniQure to seek approval for Huntington's therapy after FDA U-turn, shares skyro...
Reuters · Jun 17, 2026 Standard
UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again
biospace.com · Jun 17, 2026 Standard
UniQure stock surges after FDA U-turn clears path to gene therapy filing
fiercebiotech.com · Jun 17, 2026 Standard
In a first, a gene therapy seems to slow Huntington disease
science.org · Sep 24, 2025 Standard
The Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130 – HDBuzz
en.hdbuzz.net · Jun 17, 2026 Standard
Skyhawk reports encouraging 12-month results for oral Huntington’s disease drug SKY-0515 – HDBuzz
en.hdbuzz.net · Jun 1, 2026 Standard
Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam – HDBuzz
en.hdbuzz.net · May 4, 2026 Standard
Putting it in print: oral drug branaplam lowered huntingtin, but safety concerns halted development – HDBuzz
en.hdbuzz.net · Feb 12, 2026 Standard
A hitch in the stitch reveals why DNA sequence patterns matter in Huntington’s disease – HDBuzz
en.hdbuzz.net · Feb 9, 2026 Standard